Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16548595 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL17710515 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL11489230 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL16548548 | 0.97 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL18659469 | 0.94 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL25811209 | 0.88 | — | — | |
| SCHEMBL18899422 | 0.88 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL19221084 | 0.88 | — | — | |
| SCHEMBL16493440 | 0.85 | — | — | |
| SCHEMBL10181812 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041041-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG | 2012-02-16 | — | — | US | disclosed |
| US-8076489-B2 | 3H-benzothiazol-2-one derivatives, for example, (R)-7-[2-(1,1-dimethyl-2-phenyl-ethylamino)-1-hydroxy-ethyl]-5-hydroxy-3H-benzothiazol-2-one; useful for treating conditions that are prevented or alleviated by activation of the beta 2-adrenoreceptor | NOVARTIS AG (CH) | 2011-12-13 | — | — | US | disclosed |
| US-20080096940-A1 | 5-Hydroxy-Benzothiazole Derivatives Having Beta-2-Adrenoreceptor Agonist Activity | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041041-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | ALDH1A1 525/4885 |
| US-20080096940-A1 | 5-Hydroxy-Benzothiazole Derivatives Having Beta-2-Adrenoreceptor Agonist Activity | ADRB2, ADRB1, ADRA2C | ALDH1A1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.